Zealand Pharma Shares Slip as Petrelintide Diabetes Data Leave Analysts Wanting More Zealand Pharma's amylin drug petrelintide met its main goal in a Phase 2 trial in type 2 diabetes, but weight loss and blood sugar results disappointed analysts.… by Tia Ward 12 October 2026 Business